This post was originally published on this site

Original Post from GeneomeWeb

Nanopore Researchers Developing Mutation Detection Tech With Single Molecule SensitivityVela HIV, Melanoma Assays Secure Regulatory ApprovalsThyroid Cancer Susceptibility Loci Identified In Korean PopulationFollowing Pivotal FDA Approval for Keytruda, Promega to Seek Clearance for Mismatch Repair Deficiency AssayMDx Health Launches Bladder Cancer Test, Hoping Relationships in Urology Market Will Hasten UptakeKura Oncology Taps Foundation Medicine to ID Patients for Cancer Drug TrialSystems Study Taps Cancer Gene Expression Reversal to Predict Drug ResponsePenn Researchers ID Protein Biomarkers for Pancreatic CancerAsia Genomics, CellMax Partner on Cancer Dx in Southeast AsiaTrovagene Enters Deal With Novogene for NextCollect in ChinaGenome Sequencing, Artificial Intelligence Quickly ID Clinically Actionable Cancer MutationsNeon Therapeutics’ Personalized Vaccine Approach Progresses With Combination Immunotherapy TrialASCO Guideline Update Recommends Agendia MammaPrint in 1-3-Node PatientsOncoDNA, Shchurko Sign Belarusian Distribution DealBiocartis, Exploit Technologies Ink MDx Assay Development DealBionano Genomics, Genoptix Aim to Develop Hematology Diagnostics to Replace Karyotyping, FISH AssaysQiagen Chinese Translational Medicine Venture Completes RMB 175M Series A FinancingEpigenomics Lowers Revenue Guidance for 2017Dartmouth-Led Team Wins $12.1M NIH Grant for Lung Cancer ResearchSoftware Offers Analysis Alternative for Cancer Studies Lacking Matched ControlsSEngine Precision Medicine Licenses Hutch Cancer Drug Screening AssayPromega to Seek FDA Approval, CE-IVD Mark for Microsatellite Instability AssayNGeneBio Garners CE-IVD Mark for

Continue 

Leave a comment

Your email address will not be published.


*